Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 13 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹1,205 ↑ 26.09% (1Y)

🎯 Key Takeaways

Zydus Lifesciences is in a strategic growth phase marked by strong top-line expansion and significant investment in R&D and global markets, particularly in the US and biosimilars. Despite robust revenue growth, the company is experiencing margin compression and rising leverage, reflecting a capital-intensive phase focused on long-term pipeline and market positioning rather than short-term profitability.
Revenue grew 0.6% QoQ to ₹5,269 in Q3FY25.
⚠️ Margin pressure persists due to foreign exchange volatility and rising input costs, with EBITDA margin compressing to 24.1% — a 770 bps decline YoY —

Market Cap

₹1.02 L Cr

P/E Ratio

22.5

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About ZYDUSLIFE 📊 Interactive Charts

📖 The Story

Zydus Lifesciences is in a strategic growth phase marked by strong top-line expansion and significant investment in R&D and global markets, particularly in the US and biosimilars. Despite robust revenue growth, the company is experiencing margin compression and rising leverage, reflecting a capital-intensive phase focused on long-term pipeline and market positioning rather than short-term profitability. Management emphasizes sustainable growth and ESG alignment, signaling a transition from a domestic-centric to a globally integrated pharmaceutical player.

📰 What's Happening

In Q1 FY27, Zydus reported 22% YoY revenue growth to ₹80,170 crores, driven by branded performance in the US and new product launches, including its first biosimilar, NUFYMCO™. However, EBITDA margin declined sharply to 24.1% from 31.8% YoY due to foreign exchange headwinds and rising input costs, while net profit fell 36% to ₹9,398 crores. Management highlighted progress on key pipeline assets, including priority review for Saroglitazar Magnesium in PBC and Phase III trials for Desidustat. Capex increased to ₹5,852 crores, underscoring ongoing investment in capacity and innovation. The company also completed a share buyback of ₹11,063 million in Q1 FY26, signaling confidence in valuation despite earnings volatility.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	5,011	5,140	4,369	4,505	5,534	6,208	5,237	5,269
Operating Profit	692	1,527	1,200	1,140	1,787	2,147	1,530	1,445
OPM %	25.1%	29.3%	26.2%	24.5%	29.5%	33.6%	27.9%	26.3%
Net Profit	358	1,134	803	790	1,246	1,483	920	1,026
EPS	₹2.93	₹10.74	₹7.91	₹7.80	₹11.69	₹14.11	₹9.06	₹10.17

The financial trajectory reveals a clear inflection point: while revenue growth has accelerated — up 22% YoY in Q1 FY27 — profitability has deteriorated, with EBITDA margin contracting by 770 bps and net profit declining 36% YoY. This trend aligns with management’s disclosed investments in international expansion, biosimilars, and medtech, which require sustained capex and operational scaling. The decline in operating profit margins from 33.6% in Q1 FY25 to 26.3% in Q3FY25 reflects increasing cost pressures, likely from foreign exchange volatility and higher R&D spend. Despite strong revenue momentum, the erosion in margins and rising net debt to ₹59,041 crores raises concerns about near-term earnings sustainability, even as management cites structural investments for long-term gains.

🔮 Management Outlook & What's Next

Management expressed confidence in future growth, citing a priority review for Saroglitazar Magnesium NDA in the US for PBC and initiation of Phase III trials for Desidustat, a potential first-in-class therapy for non-dialysis CKD. They emphasized ongoing development of biosimilars and expansion of branded sales in North America as key growth vectors. The company also underscored its ESG commitments and pipeline momentum as foundations for sustainable growth. While no formal financial guidance was provided beyond qualitative statements, management reiterated focus on 'robust branded growth' and 'strategic capital allocation' to support long-term value creation.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Margin pressure persists due to foreign exchange volatility and rising input costs, with EBITDA margin compressing to 24.1% — a 770 bps decline YoY — despite revenue growth. 2. Net debt has increased to ₹59,041 crores, raising concerns about financial flexibility, though leverage ratios remain manageable. 3. Regulatory uncertainty in the US and EU markets, particularly for complex generics and biosimilars, could delay revenue realization. 4. Execution risk in scaling international operations and biosimilar commercialization may impact profitability timelines, making near-term earnings sustainability a key investor concern.

📋 Recent Filings

🧠 Analyst's Read

Zydus Lifesciences is executing a clear strategic pivot toward global specialty and biosimilar markets, supported by strong revenue growth and pipeline progress. However, investors must weigh this against near-term margin compression and rising leverage. The company’s long-term potential hinges on successful US launches of Saroglitazar and Desidustat, as well as biosimilar adoption. The next key watchpoints are US regulatory outcomes, margin recovery trends, and whether capex efficiency improves. While fundamentals remain sound, earnings volatility will likely persist, demanding close monitoring of execution and capital allocation discipline.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ZYDUSLIFE

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-13.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day